Raymond L Comenzo

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Multiple myeloma. Clinical practice guidelines in oncology
    Kenneth C Anderson
    J Natl Compr Canc Netw 5:118-47. 2007
  2. ncbi request reprint Autologous stem cell transplantation for primary systemic amyloidosis
    Raymond L Comenzo
    Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 99:4276-82. 2002
  3. ncbi request reprint Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins
    Raymond L Comenzo
    Howard 802, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Blood 107:3489-91. 2006
  4. ncbi request reprint Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis
    Raymond L Comenzo
    Cytotherapy Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Contrib Nephrol 153:195-210. 2007
  5. ncbi request reprint Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation
    R L Comenzo
    Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, N Y, USA
    Br J Haematol 106:744-51. 1999
  6. ncbi request reprint Managing systemic light-chain amyloidosis
    Raymond L Comenzo
    Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Natl Compr Canc Netw 5:179-87. 2007
  7. ncbi request reprint Systemic immunoglobulin light-chain amyloidosis
    Raymond L Comenzo
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Lymphoma Myeloma 7:182-5. 2006
  8. ncbi request reprint Amyloidosis
    Raymond L Comenzo
    Hematology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Treat Options Oncol 7:225-36. 2006
  9. ncbi request reprint Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation
    R L Comenzo
    Hematology Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Leukemia 20:345-9. 2006
  10. ncbi request reprint The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden
    R L Comenzo
    Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Blood 98:714-20. 2001

Detail Information

Publications25

  1. ncbi request reprint Multiple myeloma. Clinical practice guidelines in oncology
    Kenneth C Anderson
    J Natl Compr Canc Netw 5:118-47. 2007
  2. ncbi request reprint Autologous stem cell transplantation for primary systemic amyloidosis
    Raymond L Comenzo
    Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 99:4276-82. 2002
    ..We discuss such a risk-adapted approach to melphalan dosing in detail and conclude with a brief overview of current research using SCT to treat patients with AL...
  3. ncbi request reprint Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins
    Raymond L Comenzo
    Howard 802, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Blood 107:3489-91. 2006
    ..These results justify further study of screening for hereditary variants in patients with apparent AL, and highlight the need for practical techniques for identifying fibrils extracted from tissue...
  4. ncbi request reprint Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis
    Raymond L Comenzo
    Cytotherapy Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Contrib Nephrol 153:195-210. 2007
    ..The use of novel antibody-based approaches for imaging amyloid and possibly for accelerating removal of deposits is under active investigation...
  5. ncbi request reprint Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation
    R L Comenzo
    Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, N Y, USA
    Br J Haematol 106:744-51. 1999
    ..These findings indicate that there are important associations in AL amyloidosis among Ig VL gene utilization, organ-system tropism and post-SCT survival...
  6. ncbi request reprint Managing systemic light-chain amyloidosis
    Raymond L Comenzo
    Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Natl Compr Canc Netw 5:179-87. 2007
    ..New agents such as bortezomib and lenalidomide have shown promising activity, and novel antibody-based approaches for imaging amyloid and accelerating removal of deposits are being actively investigated...
  7. ncbi request reprint Systemic immunoglobulin light-chain amyloidosis
    Raymond L Comenzo
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Lymphoma Myeloma 7:182-5. 2006
    ..New agents, such as bortezomib and lenalidomide, have shown promising activity, and novel monoclonal antibody approaches are also under active investigation...
  8. ncbi request reprint Amyloidosis
    Raymond L Comenzo
    Hematology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Treat Options Oncol 7:225-36. 2006
    ..Drugs effective in multiple myeloma are usually helpful in AL amyloidosis if tolerated. The use of novel antibody-based approaches for imaging amyloid and possibly for accelerating removal of deposits is under active investigation...
  9. ncbi request reprint Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation
    R L Comenzo
    Hematology Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Leukemia 20:345-9. 2006
    ..PFS for those with CR or nCR was 3.1 years while for those with stable disease (SD) it was 1.3 years (P=0.06). We conclude that carmustine can be combined with HDM for myeloma with minimal pulmonary toxicity and a high response rate...
  10. ncbi request reprint The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden
    R L Comenzo
    Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Blood 98:714-20. 2001
    ..These data support the hypothesis that germ line gene use and plasma cell burden influence the organ tropism of AL. (Blood. 2001;98:714-720)..
  11. ncbi request reprint Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial
    Adam D Cohen
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 139:224-33. 2007
    ..Risk-adapted SCT with adjuvant thal/dex is feasible and results in low TRM and high haematological and organ response rates in AL patients...
  12. pmc Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan
    Ping Zhou
    Sloan Kettering Institute, Department of Pathology, New York, NY 10021, USA
    Blood 111:549-57. 2008
    ....
  13. doi request reprint Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease
    Heather Landau
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Leuk Lymphoma 53:275-81. 2012
    ..All patients undergoing stem cell harvest had a successful collection. BDD followed by TD or BTD is effective initial therapy for this population with higher-risk myeloma and results in rapid disease control and a high response rate...
  14. pmc CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy
    Ping Zhou
    Sloan Kettering Institute, Department of Medicine, New York, NY 10021, USA
    Blood 111:3403-6. 2008
    ..These data provide a rationale for the novel therapeutic targeting of CD32B using the humanized 2B6 MoAb in patients with systemic AL-amyloidosis...
  15. ncbi request reprint Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma
    Cyrus V Hedvat
    Laboratory of Molecular Aspects of Hematopoiesis, Sloan Kettering Institute, New York, NY, USA
    Br J Haematol 122:728-44. 2003
    ..Defining how malignant plasma cell growth is regulated in the bone marrow versus at extramedullary sites will help to delineate the mechanisms underlying the dependence of tumour cell growth on angiogenesis and cell adhesion...
  16. doi request reprint Clinical and echocardiographic correlates of elevated troponin in amyloid light-chain cardiac amyloidosis
    Teimuraz Apridonidze
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Am J Cardiol 110:1180-4. 2012
    ..Among baseline variables, it is the strongest predictor of all-cause mortality in multivariate analysis. Troponin is a powerful tool in clinical and prognostic assessments of patients with CAL...
  17. doi request reprint Frequencies and types of arrhythmias in patients with systemic light-chain amyloidosis with cardiac involvement undergoing stem cell transplantation on telemetry monitoring
    Yuliya B Goldsmith
    Cardiology Department, New York Methodist Hospital, New York, NY, USA
    Am J Cardiol 104:990-4. 2009
    ..Continuous telemetric monitoring contributed to patient safety during SCT...
  18. ncbi request reprint Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo
    Ping Zhou
    Sloan Kettering Institute, New York, NY, USA
    Br J Haematol 128:636-44. 2005
    ..A better understanding of ATO resistance will enable ATO to be combined with other agents for MM...
  19. ncbi request reprint Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contamination
    Ping Zhou
    Department of Medicine, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Blood 102:477-9. 2003
    ..1%) or 0.5 x 10(4) clonotypic cells per kilogram (range, 0-41.2 x 10(4)/kg), and contamination correlated with CD34+ cells collected (r2 = 0.42, P <.01). Melphalan-mobilized SCCs contain minimal clonotypic contamination...
  20. ncbi request reprint Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma
    Hani Hassoun
    Division of Hematologic Oncology, Department of Medicine, Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 132:155-61. 2006
    ..AD-TD administered with low dose aspirin for deep vein thrombosis prophylaxis was well tolerated and yielded a high response rate with minimal treatment-related morbidity...
  21. doi request reprint The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells
    Heather J Landau
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Mol Cancer Ther 11:1781-8. 2012
    ..These data provide a rationale for testing these combinations in patients with relapsed and/or refractory multiple myeloma...
  22. doi request reprint Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego)
    Angela Dispenzieri
    Department of Medicine, Division of Hematology, Mayo Clinic, 200 First Street, SW, Rochester, Minnesota 55905, USA
    Biol Blood Marrow Transplant 14:6-11. 2008
    ..Whenever possible, patients should be treated on clinical trials...
  23. ncbi request reprint Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease
    Madhav V Dhodapkar
    Laboratory of Tumor Immunology and Immunotherapy, The Rockefeller University, New York, NY 10021, USA
    Cancer Immun 3:9. 2003
    ..These data suggest that CT antigens may have important biological implications in malignant gammopathies and that CT-7 may be a suitable target for T cell-based and possibly antibody-mediated immunotherapy of myeloma...
  24. ncbi request reprint Myelopathy from Waldenström's macroglobulinemia: improvement after Rituximab therapy
    Bernardo Liberato
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Neurooncol 63:207-11. 2003
    ..We report a rare case of a patient presenting with a slowly progressive myelopathy due to WM who had a marked response to Rituximab therapy...
  25. ncbi request reprint High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis
    Raymond L Comenzo
    N Engl J Med 358:92; author reply 92-3. 2008